Blood and Lymphatic Cancer: Targets and Therapy
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report
(2870) Total Article Views
Authors: Ibeas P, Cantos B, Provencio M.
Published Date November 2011
Volume 2011:1 Pages 19 - 22
Patricia Ibeas, Blanca Cantos, Mariano Provencio
Clinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, Spain
Abstract: Hodgkin’s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refractory disease occurs in 10%–15% of cases and is still a clinical challenge. Its treatment is based on intensive chemotherapy regimens with transplantation, but there are patients who relapse after transplantation who have a poor prognosis. At this point in time, there is a lack of effective treatment options with proven efficacy and there is a real need to investigate new treatment drugs with different mechanisms of action. A persistent activation of mTOR signaling has been identified in leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma. Everolimus, an mTOR kinase inhibitor, is being used as an option in these cases with encouraging results. Here, the authors report their experience with a patient treated with everolimus.
Keywords: everolimus, positron emission tomography, chemotherapy
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- MLA'14 -
May 16–21, 2014
- Cancer Pharmacogenomics and Targeted Therapies
17 - 19 September, 2014
- ESMO 2014 Congress
26 - 30 September, 2014
- Treatment of anemia in chronic kidney disease: known, unknown, and both
- Treatment of hemophilia: a review of current advances and ongoing issues
- Use of sulodexide in patients with peripheral vascular disease
- Deep vein thrombosis: a clinical review